Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Ezabenlimab by Boehringer Ingelheim International for Triple-Negative Breast Cancer (TNBC): Likelihood of Approval
Ezabenlimab is under clinical development by Boehringer Ingelheim International and currently in Phase II for Triple-Negative Breast Cancer (TNBC). According...
Ezabenlimab by Boehringer Ingelheim International for Colorectal Cancer: Likelihood of Approval
Ezabenlimab is under clinical development by Boehringer Ingelheim International and currently in Phase II for Colorectal Cancer. According to GlobalData,...
Ezabenlimab by Boehringer Ingelheim International for Gastric Cancer: Likelihood of Approval
Ezabenlimab is under clinical development by Boehringer Ingelheim International and currently in Phase I for Gastric Cancer. According to GlobalData,...
Ezabenlimab by Boehringer Ingelheim International for Non-Small Cell Lung Cancer: Likelihood of Approval
Ezabenlimab is under clinical development by Boehringer Ingelheim International and currently in Phase II for Non-Small Cell Lung Cancer. According...
Ezabenlimab by Boehringer Ingelheim International for Solid Tumor: Likelihood of Approval
Ezabenlimab is under clinical development by Boehringer Ingelheim International and currently in Phase II for Solid Tumor. According to GlobalData,...
Ezabenlimab by Boehringer Ingelheim International for Metastatic Biliary Tract Cancer: Likelihood of Approval
Ezabenlimab is under clinical development by Boehringer Ingelheim International and currently in Phase II for Metastatic Biliary Tract Cancer. According...
Ezabenlimab by Boehringer Ingelheim International for Gastric Cancer: Likelihood of Approval
Ezabenlimab is under clinical development by Boehringer Ingelheim International and currently in Phase I for Gastric Cancer. According to GlobalData,...